JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用

doi:10.35541/cjd.20190282

Abstract

Abstract: 【Abstract】 Janus kinase-signal transducer and activator of transcription （JAK-STAT） signaling pathway plays an important role in immune pathways in atopic dermatitis （AD）. Drugs that block the JAK-STAT signaling pathway, such as classic JAK inhibitors tofacitinib, ruxolitinib, etc., have been gradually applied to the treatment of AD in clinical trials, and good clinical efficacy has been achieved. In addition, other inhibitors of the JAK-STAT signaling pathway, such as apamin and dupilumab, also show some efficacy in the treatment of AD. This review summarizes recent studies on the JAK-STAT signaling pathway and its inhibitors.

Key words: Dermatitis, atopic, Janus kinases, STAT transcription factors, JAK/STAT inhibitor

zhangZhang Zengyunou, Cai Xinying, Xiao Fengli. JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis[J]. Chinese Journal of Dermatology, 2020, 53(8): 661-664.doi:10.35541/cjd.20190282

References ［36］

［1］	Gandhi NA, Pirozzi G, Graham N. Commonality of the IL⁃4/IL⁃13 pathway in atopic diseases［J］. Expert Rev Clin Immunol, 2017,13（5）:425⁃437. doi: 10.1080/1744666X.2017.1298443.
［2］	Sullivan M, Silverberg NB. Current and emerging concepts in atopic dermatitis pathogenesis［J］. Clin Dermatol, 2017,35（4）:349⁃353. doi: 10.1016/j.clindermatol.2017.03.006.
［3］	Lee DE, Clark AK, Tran KA, et al. New and emerging targeted systemic therapies: a new era for atopic dermatitis［J］. J Dermatolog Treat, 2018,29（4）:364⁃374. doi: 10.1080/09546634. 2017.1373736.
［4］	Saleem MD, Oussedik E, D′Amber V, et al. Interleukin⁃31 pathway and its role in atopic dermatitis: a systematic review［J］. J Dermatolog Treat, 2017,28（7）:591⁃599. doi: 10.1080/09546634. 2017.1290205.
［5］	Lloyd CM, Snelgrove RJ. Type 2 immunity: expanding our view［J］. Sci Immunol, 2018,3（25）:eaat1604. doi: 10.1126/sciimmunol. aat1604.
［6］	Yagi R, Nagai H, Iigo Y, et al. Development of atopic dermatitis⁃like skin lesions in STAT6⁃deficient NC/Nga mice［J］. J Immunol, 2002,168（4）:2020⁃2027. doi: 10.4049/jimmunol.168.4. 2020.
［7］	Bao L, Shi VY, Chan LS. IL⁃4 regulates chemokine CCL26 in keratinocytes through the Jak1, 2/Stat6 signal transduction pathway: implication for atopic dermatitis［J］. Mol Immunol, 2012,50（1⁃2）:91⁃97. doi: 10.1016/j.molimm.2011.12.008.
［8］	Damsky W, King BA. JAK inhibitors in dermatology: the promise of a new drug class［J］. J Am Acad Dermatol, 2017,76（4）:736⁃744. doi: 10.1016/j.jaad.2016.12.005.
［9］	Alves de Medeiros AK, Speeckaert R, Desmet E, et al. JAK3 as an emerging target for topical treatment of inflammatory skin diseases［J/OL］. PLoS One, 2016,11（10）:e0164080. doi: 10.1371/journal.pone.0164080.
［10］	Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.
［11］	Kostovic K, Gulin SJ, Mokos ZB, et al. Tofacitinib, an oral Janus Kinase inhibitor: perspectives in dermatology［J］. Curr Med Chem, 2017,24（11）:1158⁃1167. doi: 10.2174/1874467210666170113 104503.
［12］	Meyer DM, Jesson MI, Li X, et al. Anti⁃inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP⁃690,550, in rat adjuvant⁃induced arthritis［J］. J Inflamm （Lond）, 2010,7:41. doi: 10.1186/1476⁃9255⁃7⁃41.
［13］	Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib （CP⁃690,550）［J］. J Immunol, 2011,186（7）:4234⁃4243. doi: 10.4049/jimmunol.100 3668.
［14］	Kontzias A, Kotlyar A, Laurence A, et al. Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease［J］. Curr Opin Pharmacol, 2012,12（4）:464⁃470. doi: 10.1016/j.coph.2012. 06.008.
［15］	Kubo S, Nakayamada S, Sakata K, et al. Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system［J］. Front Immunol, 2018,9:1510. doi: 10.3389/fimmu.2018.01 510.
［16］	Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate［J］. J Am Acad Dermatol, 2015,73（3）:395⁃399. doi: 10.1016/j.jaad.2015.06.045.
［17］	Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis［J］. N Engl J Med, 2010,363（12）:1117⁃1127. doi: 10.1056/NEJMoa1002028.
［18］	Verstovsek S, Mesa RA, Gotlib J, et al. A double⁃blind, placebo⁃controlled trial of ruxolitinib for myelofibrosis［J］. N Engl J Med, 2012,366（9）:799⁃807. doi: 10.1056/NEJMoa1110557.
［19］	Plosker GL. Ruxolitinib: a review of its use in patients with myelofibrosis［J］. Drugs, 2015,75（3）:297⁃308. doi: 10.1007/s40265⁃015⁃0351⁃8.
［20］	He H, Guttman⁃Yassky E. JAK inhibitors for atopic dermatitis: an update［J］. Am J Clin Dermatol, 2019,20（2）:181⁃192. doi: 10.1007/s40257⁃018⁃0413⁃2.
［21］	Guttman⁃Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate⁃to⁃severe atopic dermatitis: a phase 2 parallel, double⁃blinded, randomized placebo⁃controlled multiple⁃dose study［J］. J Am Acad Dermatol, 2019,80（4）:913⁃921.e9. doi: 10.1016/j.jaad.2018.01.018.
［22］	Tanimoto A, Shinozaki Y, Yamamoto Y, et al. A novel JAK inhibitor JTE⁃052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents［J］. Exp Dermatol, 2018,27（1）:22⁃29. doi: 10.1111/exd.13370.
［23］	Amano W, Nakajima S, Kunugi H, et al. The Janus kinase inhibitor JTE⁃052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling［J］. J Allergy Clin Immunol, 2015,136（3）:667⁃677.e7. doi: 10.1016/j.jaci.2015.03.051.
［24］	Nakagawa H, Nemoto O, Yamada H, et al. Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE⁃052 （a novel Janus kinase inhibitor） ointment in Japanese healthy volunteers and patients with atopic dermatitis［J］. J Dermatol, 2018,45（6）:701⁃709. doi: 10.1111/1346⁃8138.14322.
［25］	Wright HL, Cross AL, Edwards SW, et al. Effects of IL⁃6 and IL⁃6 blockade on neutrophil function in vitro and in vivo［J］. Rheumatology （Oxford）, 2014,53（7）:1321⁃1331. doi: 10.1093/rheumatology/keu035.
［26］	Kim WH, An HJ, Kim JY, et al. Apamin inhibits TNF⁃α⁃ and IFN⁃γ⁃induced inflammatory cytokines and chemokines via suppressions of NF⁃κB signaling pathway and STAT in human keratinocytes［J］. Pharmacol Rep, 2017,69（5）:1030⁃1035. doi: 10.1016/j.pharep.2017.04.006.
［27］	Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate⁃to⁃severe atopic dermatitis［J］. N Engl J Med, 2014,371（2）:130⁃139. doi: 10.1056/NEJMoa1314768.
［28］	Simpson EL, Gadkari A, Worm M, et al. Dupilumab therapy provides clinically meaningful improvement in patient⁃reported outcomes （PROs）: a phase IIb, randomized, placebo⁃controlled, clinical trial in adult patients with moderate to severe atopic dermatitis （AD）［J］. J Am Acad Dermatol, 2016,75（3）:506⁃515. doi: 10.1016/j.jaad.2016.04.054.
［29］	Thaçi D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate⁃to⁃severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo⁃controlled, dose⁃ranging phase 2b trial［J］. Lancet, 2016,387（10013）:40⁃52. doi: 10.1016/S0140⁃6736（15）00388⁃8.
［30］	Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis［J］. Expert Rev Clin Pharmacol, 2018,11（5）:467⁃474. doi: 10.1080/17512433.2018.1449642.
［31］	Hou DD, Di ZH, Qi RQ, et al. Sea buckthorn （hippophaë rhamnoides L.） oil improves atopic dermatitis⁃like skin lesions via inhibition of NF⁃κB and STAT1 activation［J］. Skin Pharmacol Physiol, 2017,30（5）:268⁃276. doi: 10.1159/000479 528.
［32］	Tsuji G, Takahara M, Uchi H, et al. Identification of ketoconazole as an AhR⁃Nrf2 activator in cultured human keratinocytes: the basis of its anti⁃inflammatory effect［J］. J Invest Dermatol, 2012,132（1）:59⁃68. doi: 10.1038/jid.2011.194.
［33］	Takemura M, Nakahara T, Hashimoto⁃Hachiya A, et al. Glyteer, soybean tar, impairs IL⁃4/Stat6 signaling in murine bone marrow⁃derived dendritic cells: the basis of its therapeutic effect on atopic dermatitis［J］. Int J Mol Sci, 2018,19（4）:1169. doi: 10.3390/ijms19041169.
［34］	Park JW, Lee HS, Lim Y, et al. Rhododendron album blume extract inhibits TNF⁃α/IFN⁃γ⁃induced chemokine production via blockade of NF⁃κB and JAK/STAT activation in human epidermal keratinocytes［J］. Int J Mol Med, 2018,41（6）:3642⁃3652. doi: 10.3892/ijmm.2018.3556.
［35］	Lee JH, Choi CS, Bae IH, et al. A novel, topical, nonsteroidal, TRPV1 antagonist, PAC⁃14028 cream improves skin barrier function and exerts anti⁃inflammatory action through modulating epidermal differentiation markers and suppressing Th2 cytokines in atopic dermatitis［J］. J Dermatol Sci, 2018. doi: 10.1016/j.jdermsci.2018.04.017.
［36］	Kang NJ, Han SC, Kang GJ, et al. Diphlorethohydroxycarmalol inhibits interleukin⁃6 production by regulating NF⁃κB, STAT5 and SOCS1 in lipopolysaccharide⁃stimulated RAW264.7 cells［J］. Mar Drugs, 2015,13（4）:2141⁃2157. doi: 10.3390/md13042141.

[1]	Song Zhiqiang, Chen Qiquan, Ge Lan. Insights into the progress in targeted therapy of atopic dermatitis from the perspective of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(8): 718-723.
[2]	He Xie, Li Yuzhen. Targeting the JAK-STAT signaling pathway in the treatment of psoriasis [J]. Chinese Journal of Dermatology, 2023, 56(3): 273-278.
[3]	Liu Bo, Song Xiaoting, Liao Shuanglu, Yu Miao, Luan Tingting, Li Ruoyu, Zhao Zuotao. Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 55(4): 304-307.
[4]	Tian Jing, Liang Yuan, Shen Chunping, Zhao Mutong, Wang Yang, Wang Shan, Jiao Lei, Ma Lin. Analysis of short-term efficacy and safety of the first subcutaneous injection of dupilumab in the treatment of moderate-to-severe childhood atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 299-303.
[5]	Hua Weiwei, Gong Chunyan. Application of JAK inhibitors in the treatment of refractory dermatomyositis [J]. Chinese Journal of Dermatology, 2021, 54(3): 264-267.
[6]	Song Zhiqiang, Wang Huan. Advances in the treatment of atopic dermatitis: new medications, new methods and new models [J]. Chinese Journal of Dermatology, 2021, 54(2): 161-164.
[7]	Li Ming, Zhou Lihong, Li Linfeng. Prospects of Janus kinase inhibitors in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2020, 53(10): 845-848.
[8]	Chen Yiwen, Su Ting, Su Zhonglan. Association between psoriasis and STAT3 [J]. Chinese Journal of Dermatology, 2019, 52(7): 502-505.
[9]	Yu Lijuan, Lyu Zhongfa. JAK inhibitors for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2019, 52(5): 343-346.
[10]	. Effects of tacrolimus on the secretion of chemokines CXCL9 and CXCL10 by γ-interferon-simulated HaCaT cells [J]. Chinese Journal of Dermatology, 2018, 51(5): 375-378.
[11]	LU Dang-Qing, CHEN Hong-Dun. Study of IgE-bearing Langerhans cells in lesions of atopic dermatitis and other dermatoses [J]. Chinese Journal of Dermatology, 1993, 26(4): 221-223.

JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［36］

Related Articles 11

Metrics

Comments

Recommended 10